Advertisement

Neuroscience and Behavioral Physiology

, Volume 47, Issue 9, pp 1029–1036 | Cite as

Effects of Quercetin on Neurodegenerative and Compensatory Processes in the Nigrostriatal System in a Model of the Preclinical Stage of Parkinson’s Disease in Rats

  • I. V. EkimovaEmail author
  • D. V. Plaksina
Article

Data obtained over the last ten years on the involvement of molecular chaperones of the heat shock protein 70 (HSP70) family in the pathogenesis of Parkinson’s disease (PD) do not provide an answer to the question of whether a decrease in the expression of stress-inducible Hsp70 in the brain is one of the causes of progression of neurodegeneration in PD. The present study used the HSP expression inhibitor quercetin in a model of proteasomal dysfunction in the nigrostriatal system in rats created by microinjection of the proteasome inhibitor lactacystin into the compact zone of the substantia nigra (SNc). This model reproduces subthreshold levels of nigrostriatal system degradation and neurochemical changes present in the preclinical stage of PD. We provide the first demonstration that preventive administration of quercetin prevents LC-induced Hsp70 expression in SNc neurons and leads to a 1.5-fold increase in the degeneration of dopaminergic neurons in the SNc and a 2.7-fold increase in the number of dopaminergic neuron axons in the striatum, with depletion of compensation processes and HSP70 reserves in SNc neurons. Signs of motor dysfunction typical of the clinical stage of PD were seen. The study results confirm the important role of Hsp70 in the mechanisms of protection of the nigrostriatal system in proteasomal dysfunction typical of the preclinical stage of PD. These data may provide scientific grounds for developing new techniques for the early treatment of PD based on Hsp70 preparations.

Keywords

Parkinson’s disease Hsp70 chaperonin quercetin ubiquitin-proteasomal system lactacystin neuro de generation substantia nigra rats 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    E. I. Gusev, A. B. Gekht, G. R. Popov, et al., “Parkinson’s disease. Clinical features, diagnosis, and treatment,” in: Neurodegenerative Diseases: Basic and Applied Aspects, M. V. Ugryumov (ed.), Nauka, Moscow (2010), pp. 52–86.Google Scholar
  2. 2.
    I. V. Ekimov, D. V. Plaksina, I. V. Guzhova, and D. A. Meshalkina, “The role of inducible protein Hsp70 in the modulation of neurodegenerative pathology of the nigrostriatal system typical of Parkin son’s disease,” Zh. Evolyuts. Biokhim. Fiziol., 52, No. 1, 73–75 (2016).Google Scholar
  3. 3.
    S. N. Illarioshkin, “Treatment of Parkinson’s disease and approaches to early diagnosis,” in: Parkinson’s Disease and Movement Disorders. Handbook for Physicians. Based on Proceedings of the Second National Congress on Parkinson’s Disease and Motor Disorders, S. N. Illarioshkin and O. S. Levin (eds.), Serebr. Niti, Moscow (2011), pp. 41–47.Google Scholar
  4. 4.
    Yu. F. Pastukhov, “Changes in the characteristics of paradoxical sleep – an early sign of Parkinson’s disease,” Zh. Vyssh. Nerv. Deyat., 63, No. 1, 75–85 (2013).Google Scholar
  5. 5.
    Yu. F. Pastukhov, I. V. Ekimova, I. V. Gruzhova, et al., “Content of chaperonin Hsp70 in dopaminergic neurons of the substantia nigra increases in proteasomal dysfunction,” Ros. Fiziol. Zh., 97, No. 7, 649–660 (2011).Google Scholar
  6. 6.
    Yu. F. Pastukhov, I. V. Ekimova, and A. V. Chesnokova, “Molecular mechanisms of the pathogenesis of Parkinson’s disease and perspectives for preventive therapy,” in: Neurodegenerative Diseases – from Genome to the Whole Body, Chap. 1, Motor Function and its Regulation in Health and Disease, M. V. Ugryumov (ed.), Nauch. Mir, Moscow (2014), pp. 316–355.Google Scholar
  7. 7.
    Yu. F. Pastukhov, D. V. Plaksina, K. V. Lapshina, et al., “Exogenous Hsp70 protein terminates the process of neurodegeneration in a model of the clinical stage of Parkinson’s disease in rats,” Dokl. Akad. Nauk, 457, No. 1, 225–227 (2014).Google Scholar
  8. 8.
    Yu. F. Pastukhov, A. V. Chesnokova, A. A. Yakimchuk, et al., “Changes in sleep on degeneration of substantia nigra neurons induced by the proteasome inhibitor lactacystin,” Ros. Fiziol. Zh., 96, No. 12, 1190–1202 (2010).Google Scholar
  9. 9.
    M. V. Ugryumov, “Traditional and novel concepts of the pathogenesis, diagnosis, and treatment of neurodegenerative diseases,” in: Neurodegenerative Diseases: Basic and Applied Aspects, M. V. Ugryumov (ed.), Nauka, Moscow (2010), pp. 8–35.Google Scholar
  10. 10.
    P. K. Auluck, H. E. Chan, J. Q. Trojanowski, et al., “Chaperone suppression of alpha-synuclein toxicity in a Drosophila model for Parkinson’s disease,” Science, 295, 865–868 (2002).CrossRefPubMedGoogle Scholar
  11. 11.
    N. Awasthi and B. J. Wagner, “Upregulation of heat shock protein expression by proteasome inhibition: an antiapoptotic mechanism in the lens,” Invest. Ophthalmol. Vis. Sci., 46, No. 6, 2082–2091 (2005).CrossRefPubMedGoogle Scholar
  12. 12.
    E. Bezard and C. E. Cross, “Compensatory mechanisms in experimental and human parkinsonism: towards a dynamic approach,” Prog. Neurobiol., 55, No. 2, 93–116 (1998).CrossRefPubMedGoogle Scholar
  13. 13.
    Y. Chu, H. Dodiya, P. Aebischer, et al., “Alterations in lysosomal and proteasomal markers in Parkinson’s disease: relationship to alpha-synuclein inclusions,” Neurobiol. Dis., 35, No. 3, 385–398 (2009).CrossRefPubMedGoogle Scholar
  14. 14.
    L. M. L. De Lau and M. M. B. Breteler, “Epidemiology of Parkinson’s disease,” Lancet Neurol., 5, No. 6, 525–535 (2006).CrossRefPubMedGoogle Scholar
  15. 15.
    Z. Dong, D. P. Wolfer, H. P. Lipp, and H. Büeler, “Hsp70 gene transfer by adeno-associated virus inhibits MPTP-induced nigrostriatal degeneration in the mouse model of Parkinson disease,” Mol. Ther., 11, 80–88 (2005).Google Scholar
  16. 16.
    D. Ebrahimi-Fakhari, L. J. Saidi, and L. Wahlster, “Molecular chaperones and protein folding as therapeutic targets in Parkinson’s disease and other synucleinopathies,” Acta Neuropathol. Commun., 1, No. 1, 79–94 (2013).CrossRefPubMedPubMedCentralGoogle Scholar
  17. 17.
    D. Ebrahimi-Fakhari, L. Wahlster, and P. J. McLean, “Protein degradation pathways in Parkinson’s disease: curse or blessing,” Acta Neuropathol., 124, No. 2, 153–172 (2012).CrossRefPubMedPubMedCentralGoogle Scholar
  18. 18.
    F. Fomai, P. Lenzi, M. Gesi, et al., “Fine structure and biochemical mechanisms underlying nigrostriatal inclusions and cell death after proteasome inhibition,” J. Neurosci., 23, 8955–8966 (2003).Google Scholar
  19. 19.
    C. Gomez, J. Santiago-Mejia, R. Ventura-Martinez, and R. Rodriguez, “The sunflower seed test: a simple procedure to evaluate forelimb motor dysfunction after brain ischemia,” Drug Dev. Res., 67, No. 752–756 (2006).Google Scholar
  20. 20.
    F. U. Hartl, A. Bracher, and M. Hayer-Hartl, “Molecular chaperones in protein folding and proteostasis,” Nature, 475, No. 7356, 324–332 (2011).Google Scholar
  21. 21.
    N. Hosokawa, K. Hirayoshi, A. Nakai, et al., “Flavonoids inhibit the expression of heat shock proteins,” Cell Struct. Funct., 15, No. 6, 393–401 (1990).CrossRefPubMedGoogle Scholar
  22. 22.
    K. A. Jellinger, “Neuropathobiology of non-motor symptoms in Parkinson’s disease,” J. Neural Transm., 122, No. 10, 1429–1440 (2015).CrossRefPubMedGoogle Scholar
  23. 23.
    D. R. Jones, S. Moussaud, and P. McLean, “Targeting heat shock proteins to modulate α-synuclein toxicity,” Ther. Adv. Neurol. Disord., 7, No. 1, 33–51 (2014).CrossRefPubMedPubMedCentralGoogle Scholar
  24. 24.
    A. V. Kalueff, T. Keisala, A. Minasyan, et al., “The regular and light-dark Suok tests of anxiety and sensorimotor integration: utility for behavioral characterization in laboratory rodents,” Nat. Protoc., 3, No. 1, 129–136 (2008).CrossRefPubMedGoogle Scholar
  25. 25.
    Y. Kawazoe, A. Nakai, Tanabe M, and K. Nagata, “Proteasome inhibition leads to the activation of all members of the heat-shock-factor family,” Eur. J. Biochem., 255, No. 2, 356–362 (1998).Google Scholar
  26. 26.
    E. A. Kozina, G. R. Khakimova, V. G. Khaindrava, et al., “Tyrosine hydroxylase expression and activity in nigrostriatal dopaminergic neurons of MPTP-treated mice at the presymptomatic and symptomatic stages of parkinsonism,” J. Neural Sci, 340, No. 1–2, 198–207 (2014).CrossRefGoogle Scholar
  27. 27.
    J. Labbadia and R. I. Morimoto, “The biology of proteostasis in aging and disease,” Annu. Rev. Biochem., 84, 435–464 (2015).CrossRefPubMedPubMedCentralGoogle Scholar
  28. 28.
    H. A. Lashuel, C. R. Overk, A. Oueslati, and E. Masliah, “The many faces of α-synuclein: from structure and toxicity to therapeutic target,” Nat. Rev. Neurosci., 14, No. 1, 38–48 (2013).CrossRefPubMedPubMedCentralGoogle Scholar
  29. 29.
    W. Le, P. Sayana, and J. Jankovic, “Animal models of Parkinson’s disease: a gateway to therapeutics?” Neurotherapeutics, 11, No. 1, 92–110 (2014).Google Scholar
  30. 30.
    J. B. Leverenz, I. Umar, Q. Wang, et al., “Proteomic identification of novel proteins in cortical Lewy bodies,” Brain Pathol., 17, No. 2, 139–145 (2007).CrossRefPubMedGoogle Scholar
  31. 31.
    A. Mathew, S. K. Mathur, and R. I. Morimoto, “Heat shock response and protein degradation: regulation of HSF2 by the ubiquitin-proteasome pathway,” Mol. Cell Biol., 18, 5091–5098 (1998).CrossRefPubMedPubMedCentralGoogle Scholar
  32. 32.
    R. I. Morimoto, “Regulation of the heat shock transcriptional response: cross talk between a family of heat shock factors, molecular chaperones, and negative regulators,” Genes Dev., 12, No. 24, 3788–3796 (1998).CrossRefPubMedGoogle Scholar
  33. 33.
    P. Ostling, J. K. Björk, P. Roos-Mattjus, et al., “Heat shock factor 2 (HSF2) contributes to inducible expression of hsp gens through interplay with HSF1,” J. Biol. Chem., 282, No. 10, 7077–7086 (2007).CrossRefPubMedGoogle Scholar
  34. 34.
    G. Paxinos and C. Watson, The Rat Brain in Stereotaxic Coordinates, Academic Press, San Diego (1998).Google Scholar
  35. 35.
    P. Riederer and S. Wuketich, “Time course of nigrostriatal degeneration in Parkinson’s disease. A detailed study of influential factors in human brain amine analysis,” J. Neural Transm., 38, 277–301 (1976).CrossRefPubMedGoogle Scholar
  36. 36.
    F. Simunovic, M. Yi, Y. Wang, et al., “Gene expression profiling of substantia nigra dopamine neurons: further insights into Parkinson’s disease pathology,” Brain, 132, No. 7, 1795–1809 (2009).Google Scholar
  37. 37.
    M. Xilouri, O. R. Brekk, and L. Stefanis,” α-Synuclein and protein degradation systems: a reciprocal relationship,” Mol. Neurobiol., 47, No. 2, 537–551 (2013).Google Scholar

Copyright information

© Springer Science+Business Media, LLC, part of Springer Nature 2017

Authors and Affiliations

  1. 1.Sechenov Institute of Evolutionary Physiology and BiochemistryRussian Academy of SciencesSt. PetersburgRussia

Personalised recommendations